Cargando…

A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery

BACKGROUND: While loteprednol etabonate ophthalmic gel 0.5% (LE gel) is approved for treatment of postoperative ocular inflammation and pain, there have been no reported studies in patients undergoing laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK). METHODS: This w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salinger, Clifford L, Gordon, Michael, Jackson, Mitchell A, Perl, Theodore, Donnenfeld, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644184/ https://www.ncbi.nlm.nih.gov/pubmed/26609219 http://dx.doi.org/10.2147/OPTH.S94332

Ejemplares similares

Use of loteprednol for routine prophylaxis after photorefractive keratectomy
por: Mifflin, Mark D, et al.
Publicado: (2012)

Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy
por: Karimian, Farid, et al.
Publicado: (2017)

Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
por: Fong, Raymond, et al.
Publicado: (2012)

Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper
por: Mifflin, Mark D, et al.
Publicado: (2017)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

Photorefractive Keratectomy for Residual Myopia after Myopic Laser In Situ Keratomileusis
por: Solaiman, Kamal A. M., et al.
Publicado: (2017)

Herpes endotheliitis following laser-assisted in situ keratomileusis and photorefractive keratectomy
por: Moshirfar, Majid, et al.
Publicado: (2023)

Early Postoperative Pain and Visual Outcomes Following Epipolis-Laser In Situ Keratomileusis and Photorefractive Keratectomy
por: Kim, Jae-Hyung, et al.
Publicado: (2010)

Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis
por: Mah, Francis S., et al.
Publicado: (2021)

The Incidence of Central Serous Chorioretinopathy after Photorefractive Keratectomy and Laser In Situ Keratomileusis
por: Moshirfar, Majid, et al.
Publicado: (2012)

Corneal biomechanical properties after laser-assisted in situ keratomileusis and photorefractive keratectomy
por: Hwang, Eileen S, et al.
Publicado: (2017)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey, Martin J, et al.
Publicado: (2013)

Changes in Intraocular Pressure after Transepithelial Photorefractive Keratectomy and Femtosecond Laser In Situ Keratomileusis
por: Chou, Chien-Chih, et al.
Publicado: (2021)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

Comparison of microkeratome assisted sub-Bowman keratomileusis with photorefractive keratectomy
por: Althomali, Talal A.
Publicado: (2017)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
por: Sheppard, John D, et al.
Publicado: (2014)

Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
por: Sheppard, John D., et al.
Publicado: (2016)

Visual Outcomes of Conductive Keratoplasty to Treat Hyperopia and Astigmatism After Laser in situ Keratomileusis and Photorefractive Keratectomy
por: Habibollahi, Alireza, et al.
Publicado: (2011)

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard, JD, et al.
Publicado: (2019)

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
por: Comstock, Timothy L, et al.
Publicado: (2011)

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
por: Özcan, Gökçen, et al.
Publicado: (2021)

Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%
por: Cavet, Megan E., et al.
Publicado: (2019)

Management of Post Laser In Situ Keratomileusis Ectasia with Simultaneous Topography Guided Photorefractive Keratectomy and Collagen Cross-Linking
por: Kymionis, George D, et al.
Publicado: (2011)

Prospective, randomized, contralateral eye comparison of tetracaine and proparacaine for pain control in laser in situ keratomileusis and photorefractive keratectomy
por: Moshirfar, Majid, et al.
Publicado: (2014)

Comparing the Rate of Regression after Conductive Keratoplasty with or without Prior Laser-Assisted in situ Keratomileusis or Photorefractive Keratectomy
por: Moshirfar, Majid, et al.
Publicado: (2012)

A Comparison of Visual Outcomes and Patient Satisfaction Between Photorefractive Keratectomy and Femtosecond Laser-Assisted In Situ Keratomileusis
por: Hashmani, Nauman, et al.
Publicado: (2017)

Comparison of Three Tonometers in Measuring Intraocular Pressure in Eyes That Underwent Myopic Laser in situ Keratomileusis and Photorefractive Keratectomy
por: Ang, Robert Edward T, et al.
Publicado: (2022)

Effect of Transepithelial Photorefractive Keratectomy without Mitomycin C in the Treatment of Femtosecond Laser In Situ Keratomileusis Corneal Flap Complications
por: Wang, Jing, et al.
Publicado: (2021)

Role of corneal epithelial thickness during myopic regression in femtosecond laser-assisted in situ keratomileusis and transepithelial photorefractive keratectomy
por: Li, Hua, et al.
Publicado: (2022)

Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
por: Schopf, Lisa, et al.
Publicado: (2014)

Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops
por: Tampucci, Silvia, et al.
Publicado: (2023)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Differences in Simulated Refractive Outcomes of Photorefractive Keratectomy (PRK) and Laser In-Situ Keratomileusis (LASIK) for Myopia in Same-Eye Virtual Trials
por: Seven, Ibrahim, et al.
Publicado: (2019)

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
por: Deom, James E, et al.
Publicado: (2022)

Loteprednol etabonate: Dematiaceous fungal colonisation by Bipolaris species in the left eye: case report
Publicado: (2020)

Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Photorefractive Keratectomy in Keratoconus
por: Tambe, Deepali Sandeep, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hangkesavj6ecmkjvrjnd1qk6e